Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,041.28
(
0.26%
)
US TECH 100
25,613.60
(
0.46%
)
Dow Jones
48,578.72
(
0.24%
)
Brent Oil
95.01
(
2.54%
)
Bitcoin
74,990.18
(
0.22%
)
News Focus
News Focus
Post# of 48316
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Titan V

Send PM Follow Ignore
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Titan V

Re: Canoepaddler post# 26337

Tuesday, 11/25/2014 9:00:12 PM

Tuesday, November 25, 2014 9:00:12 PM

Post# of 48316
Agreed 100% that the uplist will be a bullish event in itself. I do not foresee us needing a RS. ONCS is different than other biotechs because we are working towards turning non-responders of the best in class immunotherapy drug of a multibillion $ cancer immunotherapy market to responders and making it THE ultimate solid cancer treatment drug. If P2B preliminary data is good, then as Punit has mentioned before, I foresee a smooth organic uplist.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote